Skip to main content
Download PDF

Cardiac ischemia–reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity

Cardiovascular Diabetology volume 18, Article number: 85 (2019) Cite this article

Abstract

Background

Recent large-scale clinical trials have shown that SGLT2-inhibitors reduce cardiovascular events in diabetic patients. However, the regulation and functional role of cardiac sodium–glucose cotransporter (SGLT1 is the dominant isoform) compared with those of other glucose transporters (insulin-dependent GLUT4 is the major isoform) remain incompletely understood. Given that glucose is an important preferential substrate for myocardial energy metabolism under conditions of ischemia–reperfusion injury (IRI), we hypothesized that SGLT1 contributes to cardioprotection during the acute phase of IRI via enhanced glucose transport, particularly in insulin-resistant phenotypes.

Methods and results

The hearts from mice fed a high-fat diet (HFD) for 12 weeks or a normal-fat diet (NFD) were perfused with either the non-selective SGLT-inhibitor phlorizin or selective SGLT2-inhibitors (tofogliflozin, ipragliflozin, canagliflozin) during IRI using Langendorff model. After ischemia–reperfusion, HFD impaired left ventricular developed pressure (LVDP) recovery compared with the findings in NFD. Although phlorizin-perfusion impaired LVDP recovery in NFD, a further impaired LVDP recovery and a dramatically increased infarct size were observed in HFD with phlorizin-perfusion. Meanwhile, none of the SGLT2-inhibitors significantly affected cardiac function or myocardial injury after ischemia–reperfusion under either diet condition. The plasma membrane expression of GLUT4 was significantly increased after IRI in NFD but was substantially attenuated in HFD, the latter of which was associated with a significant reduction in myocardial glucose uptake. In contrast, SGLT1 expression at the plasma membrane remained constant during IRI, regardless of the diet condition, whereas SGLT2 was not detected in the hearts of any mice. Of note, phlorizin considerably reduced myocardial glucose uptake after IRI, particularly in HFD.

Conclusions

Cardiac SGLT1 but not SGLT2 plays a compensatory protective role during the acute phase of IRI via enhanced glucose uptake, particularly under insulin-resistant conditions, in which IRI-induced GLUT4 upregulation is compromised.

Background

Although fatty acids are the predominant fuel of energy metabolism in the normal adult heart, glucose is an important preferential substrate under specific pathological conditions, such as ischemia–reperfusion injury (IRI), as it provides greater efficiency for producing high-energy products per oxygen molecule consumed than fatty acids [1,2,3,4,5,6]. During the acute phase of IRI, under conditions of impaired mitochondrial oxidative phosphorylation, increased glycolysis becomes a major mechanism by which the heart maintains ATP generation and is critical for the cardiomyocyte survival [2]. Therefore, targeting the acceleration of myocardial glucose utilization during the acute phase of IRI is a potential therapeutic strategy for protecting cardiomyocyte and improving the cardiac functional recovery [2, 5, 7, 8]. This approach may become of particular importance under insulin-resistant conditions, such as diabetes mellitus, in which the glucose utilization is further impaired in response to various stimuli, including insulin stimulation as well as ischemic insult.

Glucose utilization is initiated by the uptake of glucose via glucose transporters, which appears to be the rate-limiting step in glycolytic flux in the heart [5, 7, 9]. Glucose transporters are divided into two major families: facilitated glucose transporters (GLUTs) and sodium-coupled active transporters (SGLTs) [6, 7]. Among the 12 subtypes of GLUTs conserved in mammals, GLUT1 and GLUT4 appear to be the major glucose transporters in the heart, and GLUT4 is thought to be the most abundant, accounting for approximately 70% of glucose transporters [6, 9, 10]. GLUT4 resides mainly in the intracellular vesicles under basal conditions and is translocated to the plasma membrane in response to insulin as well as other pathological processes, such as ischemic insult. It was previously reported that GLUT4-mediated enhanced glucose transport represents an essential protective mechanism against IRI and other pathological stresses [2, 8, 9, 11, 12]. However, it was also reported that the cardiac GLUT4 expression is decreased under insulin-resistant conditions, such as diabetes, in association with the reduction in glucose uptake, leading to impaired glucose utilization in the heart [10, 13, 14].

Although the regulation and the functional roles of GLUTs in the heart have been intensively investigated in a variety of in vitro and in vivo models [2, 8, 9, 12,13,14,15], less is known about the role and functional significance of SGLTs in the heart, particularly under insulin-resistant conditions. In the heart, SGLT1, not SGLT2, is considered to be the dominant isoform [16,17,18]. Previous studies showed that SGLT1 is highly expressed in the heart, especially under conditions of ischemia [18, 19], hypertrophy [18, 20], or diabetes [19, 21], all of which were evaluated based on either the mRNA or protein expression from whole heart tissues in the relatively chronic phase. We also recently showed that SGLT1 was highly expressed in the plasma membrane fraction of the human autopsied heart as well as the murine Langendorff perfused heart, although the transmembrane protein expression was not significantly affected, at least during the acute phase of IRI [7]. Subsequently, using a murine Langendorff model, we reported that the non-selective SGLT-inhibitor phlorizin perfusion predisposes the heart to profound IRI, which was associated with a significant decrease in the cardiac tissue ATP content, as a result of a reduction in the glucose uptake as well as the glycolytic flux in the heart during ischemia–reperfusion [7]. These data suggest that cardiac SGLT1 significantly contributes to cardioprotection against IRI by replenishing the ATP stores in ischemic cardiac tissues through promoting glucose utilization. However, the regulation and functional significance of cardiac SGLT1 under insulin-resistant conditions, in which the GLUT4 expression is decreased, remain poorly understood.

Recent studies have shown that chronic excessive actions of SGLT1 actually have a detrimental impact on the heart [20, 22,23,24]. Considering that SGLT1 was reported to be chronically over-activated in the diabetic heart [19, 21, 25], the question remains whether cardiac SGLT1 detrimentally impacts the diabetic myocardium, or exerts a protective effect against ischemic insult as a compensatory mechanism for compromised GLUT4 under insulin-resistant conditions.

To better understand the role and functional significance of cardiac SGLT1 during IRI under insulin-resistant conditions, we studied the responses of phlorizin-perfused mouse hearts to IRI using high-fat diet (HFD)-induced obese mice.

Methods

Animal models

All animal procedures conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Research Committee at the Jikei University School of Medicine (2016-038C4). Male C57BL/6 mice at 8 weeks of age were fed either a HFD—consisting of 60% calories from fat, 20% from protein, and 20% from carbohydrates (D12492; Research Diets, New Brunswick, NJ, USA)—or a matched control normal-fat diet (NFD)—consisting of 10% calories from fat, 20% from protein, and 70% from carbohydrates (D12450J; Research Diets)—for 12 weeks. To investigate the dose effects of SGLT2-inhibitors on myocardial IRI, 10-week-old male ICR mice that had been fed normal chow (CE-2; CLEA Japan, Tokyo, Japan) were used.

Glucose and insulin tolerance tests

For the glucose tolerance test, mice were fasted for 16 h, anaesthetized (isoflurane, 1%, inhalation), and 1 mg/g body weight of glucose was injected intraperitoneally (i.p.). For the insulin tolerance test, mice were fasted for 2 h, and 1 U/kg body weight of insulin was injected i.p. In both tests, blood samples were collected at baseline and at 15, 30, 60, 90, and 120 min after injection, and plasma glucose concentrations were measured using a commercially available glucose meter (MEDISAFE FIT; Terumo Corporation, Tokyo, Japan).

Experiments in Langendorff hearts

After 8 to 12 h of fasting, mice were heparinized (1000 IU/kg, i.p.) and anesthetized (pentobarbital, 60 mg/kg, i.p.) in order to eliminate suffering. The heart was then rapidly excised, and the aorta was cannulated onto a Langendorff apparatus, followed by retrograde-perfusion at a constant pressure (80 mmHg) with modified Krebs–Henseleit buffer (11 mM glucose, 118 mM NaCl, 4.7 mM KCl, 2.0 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 0.5 mM EDTA), as previously described [7, 11, 26]. A temperature-regulated heart chamber was then placed around the heart in order to keep the perfused heart at a certain temperature. Cardiac hemodynamics was measured using a water-filled balloon catheter introduced into the left ventricle.

Ischemia–reperfusion model

After a stabilization period of 20 min, the control hearts were perfused for another 10 min before ischemia–reperfusion in order to measure the baseline pre-ischemia cardiac function. Subsequently, global ischemia was applied by eliminating flow followed by reperfusion, as previously described [7]. Where indicated, 10−4 mol/L of phlorizin (Sigma-Aldrich, Tokyo, Japan) used as a non-specific SGLT-inhibitor, 5 or 50 µmol/L of tofogliflozin (kindly provided by Sanofi K.K., Tokyo, Japan), 10 µmol/L of ipragliflozin (kindly provided by Astellas Pharma Inc., Ibaraki, Japan), or 15 µmol/L of canagliflozin (kindly provided by Mitsubishi Tanabe Pharma Co., Osaka, Japan), all of which were used as specific SGLT2-inhibitors, was added to the buffer during the pre-ischemia perfusion and reperfusion periods. Phlorizin and SGLT2-inhibitors were dissolved in dimethylsulfoxide (DMSO), and the solvent concentration (0.1% DMSO) was identically maintained in the control group. For the immunoblotting analysis, the individual perfused hearts were snap frozen in liquid nitrogen and stored at − 80 °C prior to protein extraction. Triphenyltetrazolium chloride (TTC) staining was performed to determine the myocardial infarct size using the individual perfused hearts after ischemia–reperfusion, as previously described [7, 11]. Briefly, hearts were sectioned from apex to base into four 2-mm sections. To delineate the infarct, sections were incubated in 5% (wt/vol) TTC in PBS at 37 °C for 20 min. For each section, the area at risk (AAR) and infarct area were measured from enlarged digital micro-graphs. Percent myocardial infarction (%MI) was calculated as the total infarction area divided by the total AAR for that heart.

Glucose uptake in Langendorff hearts

After 12 h of fasting, the rate of glucose transport in Langendorff perfused hearts was measured by detection of the amount of 2-deoxy-d-glucose (2-DG) using a 2-DG Uptake Measurement kit (Cosmo Bio Co., Ltd., Tokyo, Japan) according to the same protocol as previously described [7].

Cardiac enzyme measurement

Creatine phosphokinase (CPK) levels were measured in the effluent using an enzymatic activity assay, as previously described [7, 26]. Values were corrected for coronary flow and heart weight [CPK (U/l) × coronary flow (l/min)/heart weight (g) = U/min/g].

Cardiac muscle fractionation

The preparation and fractionation of plasma membranes from cardiac muscles was performed using Minute Plasma Membrane Protein Isolation Kit (Invent Biotechnologies, Eden Prairie, MN) according to the manufacture’s protocol as previously described [7]. After plasma membrane fractionation, the protein concentrations were determined according to a Bradford assay, and equal amounts of protein were loaded for immunoblotting.

Immunoblotting

Immunoblotting was performed as previously described [7, 26,27,28] with rabbit polyclonal anti-SGLT1 (1:200, #H-85; Santa Cruz Biotechnology, CA, USA), anti-GLUT4 (1:1000, #ab33780; Abcam, Cambridge, MA, USA), anti-GLUT1 (1:1000, #12939; Cell Signaling Technology, Tokyo, Japan), or mouse monoclonal anti-α1 Na–K-ATPase (1:1000, #ab7671; Abcam). The signals were detected using chemiluminescence.

RNA isolation, reverse transcription (RT) and real-time polymerase chain reaction (PCR)

Total RNA was extracted from the frozen tissues using TRIzol reagent (Invitrogen) and a quantitative real-time PCR was performed using a StepOnePlus Real-time PCR System and the StepOne Software program (Applied Biosystems), as described previously [28]. The real-time PCR protocol consisted of one cycle at 95 °C for 20 s followed by 40 cycles at 95 °C for 1 s and 60 °C for 20 s using the primers for Slc5a2 (Mm00453831_m1; Applied Biosystems) and GAPDH (Mn03302249_g1; Applied Biosystems). The transcriptional levels were determined using the ΔΔCt method with normalization to GAPDH.

Statistical analysis

The data are presented as the mean ± standard error of the mean of at least three independent experiments. Student’s t-test was used for the comparison of two data sets. The hemodynamic parameters, %MI determined according to TTC staining and 2-DG uptake were compared using one-way analysis of variance (AONVA) followed by post hoc Bonferroni or Turkey tests. The CPK levels were compared using Kruskal–Wallis test and Mann–Whitney U test. A value of P < 0.05 was considered to be significant.

Results

Effects of 12-week HFD feeding

After 12 weeks of HFD feeding, mice developed marked obesity with a 44% increase in body weight compared with NFD mice (Fig. 1a, b). Fasting plasma glucose levels were higher in HFD mice than in NFD mice (Fig. 1c). The glucose tolerance test (Fig. 1c) and insulin tolerance test (Fig. 1d) clearly demonstrated that 12-week HFD feeding induced glucose intolerance and insulin resistance.

Fig. 1
figure1

Twelve-week HFD feeding induced obesity, glucose intolerance, and insulin resistance in mice. a Appearance of the obese mice after 12 weeks of HFD feeding. Bars = 1 cm. b Body weight changes during HFD feeding (n = 6 each). c Plasma glucose levels during glucose tolerance tests (NFD; n = 9, HFD; n = 12). d Plasma glucose levels during insulin tolerance tests (n = 12 each). **P < 0.01 versus NFD at each time point. NFD normal-fat diet, HFD high-fat diet

Full size image

Effects of phlorizin on the cardiac function during IRI in HFD mice

The experimental protocols of ex vivo Langendorff ischemia–reperfusion (Fig. 2a) and the representative tracing of left ventricular developed pressure (LVDP) during IRI (Fig. 2b) are shown. The baseline cardiac function measured at the end of the 10-min pre-ischemia perfusion period indicated that HFD mice had increased contractile activity, consistent with the previous studies (Table 1) [29, 30]. Phlorizin-perfusion did not significantly affect the baseline cardiac function in hearts of either NFD or HFD mice. After 30-min global ischemia followed by 40-min reperfusion, HFD per se significantly reduced LVDP recovery (22.5% ± 3.5% versus 68.3% ± 7.1% recovery from baseline, P < 0.01, Fig. 2c, d) and the rate pressure product (RPP), calculated as LVDP × heart rate, in order to consider the impact of the heart rate on the cardiac function (6733 ± 1271 versus 20,610 ± 4716 mmHg bpm at the end of IRI, P < 0.01, Additional file 1: Fig. S1A) in association with an increase in left ventricular end-diastolic pressure (LVEDP) (Additional file 1: Fig. S1B) and the significant impairment of the maximum rate of contraction (+dp/dtmax) and maximum rate of relaxation (−dp/dtmin) (Additional file 1: Fig. S1C) compared with those values in NFD hearts. Although phlorizin-perfusion also impaired the cardiac functional recovery in NFD hearts (LVDP recovery rate: 29.5% ± 4.5%, P < 0.01, RPP: 9102 ± 867 mmHg bpm, P < 0.05), consistent with our previous study [7], further dramatically impaired cardiac functional recovery was observed in HFD hearts with phlorizin-perfusion (LVDP recovery rate: 7.1% ± 1.9%, RPP 2146 ± 601 mmHg bpm, P < 0.01 versus HFD without phlorizin-perfusion). These data suggest that SGLT1 is vital for the cardiac functional recovery after ischemia–reperfusion, particularly under insulin-resistant conditions.

Fig. 2
figure2

Cardiac functional recovery after ischemia–reperfusion injury with or without phlorizin-perfusion. a Experimental protocols indicating the duration and time course of ischemia/reperfusion are shown. The CPK activity released into the perfusate was measured at the point in the protocol indicated by the solid arrows. b Representative tracing of LVDP during ischemia–reperfusion with or without phlorizin-perfusion. LVDP profiles (c) and LVDP recovery (percent of baseline) (d) measured at the indicated time points during ischemia–reperfusion in NFD (open black square; n = 6), NFD phlorizin-perfused (filled black square; n = 6), HFD (open pink square; n = 8), and HFD phlorizin-perfused (filled pink square; n = 6) hearts are shown. *P < 0.05 and **P < 0.01 versus the NFD group at each time point; †P < 0.05 and ‡P < 0.01 versus the HFD group at each time point. SGLT2i SGLT2-inhibitors, min minutes, LVDP left ventricular developed pressure, I ischemia, R reperfusion

Full size image
Table 1 Baseline cardiac function of ex vivo perfused hearts with or without phlorizin-perfusion
Full size table

Cardiac injury after ischemia–reperfusion

The activity of CPK released into the perfusate during reperfusion was measured as an index of myocardial injury (Fig. 3a), and the total amount of CPK released during the entire reperfusion period, as indicated by the CPK area under the curve (AUC) for the CPK level, was also shown (Fig. 3b) [7, 11]. During the baseline pre-ischemia perfusion period, no CPK activity was detectable. After IRI, the CPK activity was significantly increased in HFD hearts compared with NFD hearts (CPK-AUC: 5.2 ± 1.7 versus 1.3 ± 0.2 U/g, P < 0.05). Although phlorizin-perfusion also increased CPK release in NFD hearts (8.3 ± 1.7 U/g, P < 0.01), consistent with our previous study [7], further dramatically increased CPK release was observed in HFD hearts with phlorizin-perfusion (23.2 ± 6.9 U/g, P < 0.05 versus HFD without phlorizin-perfusion). These findings correlated with larger infarcts in NFD hearts with phlorizin-perfusion and HFD hearts (52.5% ± 3.5% [P < 0.01] and 60.2% ± 1.5% [P < 0.01], versus 32.3% ± 2.2% [NFD], respectively), which was particularly striking in HFD hearts with phlorizin-perfusion (71.8% ± 4.0%, P < 0.05 versus HFD hearts without phlorizin-perfusion), compared with those noted in the NFD hearts (Fig. 3c, d).

Fig. 3
figure3

Myocardial injury after ischemia–reperfusion with or without phlorizin-perfusion. a CPK profiles in the effluent collected during the reperfusion period. b The area under the curve (AUC) was calculated from the CPK profile shown in a (NFD; n = 11, NFD with phlorizin-perfusion; n = 7, HFD; n = 10, HFD with phlorizin-perfusion; n = 4). *P < 0.05 and **P < 0.01 versus the NFD group at each time point; †P < 0.05 and ‡P < 0.01 versus the HFD group at each time point. c Micrograph showing representative TTC staining of cardiac sections obtained from NFD, NFD with phlorizin-perfusion, HFD, and HFD with phlorizin-perfusion groups after ischemia–reperfusion. Bars = 3 mm. d Effects on the quantitated cumulative infarct area size in NFD (n = 9), NFD phlorizin-perfused (n = 6), HFD (n = 5), and HFD phlorizin-perfused (n = 4) hearts. **P < 0.01 versus the NFD group; †P < 0.05 versus the HFD group. %MI myocardial infarct area/ventricular area

Full size image

Direct effects of selective SGLT2-inhibitors on either NFD or HFD hearts during IRI

Increasing attention has been focused on SGLT2-inhibitors as novel anti-diabetic agents that reduce cardiovascular events, as shown in recent large clinical trials [31,32,33]. We therefore next investigated the direct effects of selective SGLT2-inhibitors on the cardiac functional recovery and myocardial injury after ischemia–reperfusion in both HFD and NFD hearts.

No SGLT2 mRNA expression was detected even in HFD mouse hearts (Additional file 1: Fig. S2). Each SGLT2-inhibitor—namely 5 µM of tofogliflozin, 10 µM of ipragliflozin, or 15 µM of canagliflozin—was perfused according to the protocol of Langendorff ischemia–reperfusion using HFD hearts (Fig. 2a), and no significant effects of these SGLT2-inhibitors on the baseline cardiac function were noted (Additional file 1: Table S1). After IRI, none of the SGLT2-inhibitors significantly affected the cardiac function, including LVDP recovery after IRI, or CPK release in HFD mice (Fig. 4a–d).

Fig. 4
figure4

Cardiac functional recovery and myocardial injury after ischemia–reperfusion injury with or without SGLT2-inhibitor perfusion. LVDP profiles and myocardial injury in HFD (a–d) and NFD (e–h) mice are shown. LVDP profiles (a) and LVDP recovery (percent of baseline) (b) measured at the indicated time points during ischemia–reperfusion in the control (open pink square; n = 8, as shown in Fig. 2c, d), 5 µM tofogliflozin-perfused (blue square; n = 5), 10 µM ipragliflozin-perfused (green square; n = 6), and 15 µM canagliflozin-perfused (yellow square; n = 8) hearts are shown. CPK profiles in the effluent collected during the reperfusion period (c) and the area under the curve (AUC) (d) calculated from the CPK profile (c) are shown (control: n = 5, as shown in Fig. 3a, b; tofogliflozin perfusion: n = 5; ipragliflozin perfusion: n = 7; canagliflozin perfusion: n = 7). **P < 0.01 versus the HFD group at each time point. LVDP profiles (e) and LVDP recovery (percent of baseline) (f) measured at the indicated time points during ischemia–reperfusion in the control (open black square; n = 10), 5 µM tofogliflozin-perfused (blue square; n = 8), and 50 µM tofogliflozin-perfused (purple square; n = 8) hearts are shown. CPK profiles in the effluent collected during the reperfusion period (g) and the AUC (h) calculated from the CPK profile (g) are shown (control: n = 12; tofogliflozin [5 µM]-perfusion: n = 7; tofogliflozin [50 µM]-perfusion: n = 7). *P < 0.05 and **P < 0.01 versus control at each time point. Tofo tofogliflozin, Ipra ipragliflozin, Cana canagliflozin

Full size image

To simply assess the dose effects of SGLT2-inhibitors, either 5 or 50 µM of tofogliflozin was perfused during 20-min global ischemia followed by 40-min reperfusion in ICR mice fed normal chow. The baseline cardiac function was not affected by either dose of tofogliflozin (Additional file 1: Table S2). However, while 5 µM of tofogliflozin did not affect the cardiac function or CPK release during IRI, 50 µM of tofogliflozin significantly reduced LVDP recovery in association with an increased CPK release after IRI (Fig. 4e–h), similar to the effects observed under phlorizin-perfusion [7]. Taken together, these findings indicated no harmful effects of selective SGLT2-inhibitors during IRI, even in HFD hearts, although detrimental effects were noted at supra-pharmacological doses, possibly through non-selective SGLT1 inhibition.

The expression of glucose transporters in HFD hearts during IRI

In order to clarify the mechanisms underlying these detrimental effects of SGLT1 inhibition during IRI, particularly in HFD hearts, we next examined the dynamics of glucose transporters in these murine hearts. Immunoblotting with plasma membrane fractionation revealed that the GLUT4 expression was significantly reduced in HFD hearts compared with NFD hearts at baseline (Fig. 5a, c). The GLUT4 expression at the plasma membrane was significantly increased after IRI in NFD hearts, while the response of GLUT4 to IRI was substantially attenuated in HFD hearts (Fig. 5b, c). In contrast, the SGLT1 expression at the plasma membrane remained constant during IRI, regardless of diet conditions (Fig. 5a–c). The GLUT1 expression was also equivalent during IRI under both diet conditions (Additional file 1: Fig. S3). Likewise, the regulation of the expression of those glucose transporters was not affected by phlorizin-perfusion (Additional file 1: Fig. S4), indicating that SGLT1 inhibition negligibly influences the regulation of GLUT4 and GLUT1 expression in NFD and HFD hearts, both at baseline and after IRI. In addition, these data may rule out the possibility of the non-specific inhibitory effects of phlorizin on other glucose transporters, at least in the present experimental model.

Fig. 5
figure5

The expression of glucose transporters and the glucose uptake in myocardium during ischemia–reperfusion. Representative immunoblots of GLUT4 and SGLT1 in the plasma membrane fraction from the murine perfused hearts at baseline measured at the end of 10-min pre-ischemia perfusion (a) and before and after IRI (b) are shown. c Densitometric quantitation normalized to the level of either the GLUT4 or SGLT1 expression in NFD hearts before IRI are shown ([GLUT4] NFD or HFD without IRI: n = 8 each, NFD or HFD with IRI: n = 6 each; [SGLT1] NFD or HFD without IRI: n = 9 each, NFD or HFD with IRI: n = 7 or n = 6, respectively). *P < 0.05, **P < 0.01 versus NFD hearts before IRI; ‡P < 0.01 versus NFD hearts after IRI. In both a and b, immunoblots of Na+/K+ ATPase from the same membrane are shown as a loading control for the membrane fraction. d Glucose uptake in NFD (open black square), NFD phlorizin-perfused (filled black square), HFD (open pink square), and HFD phlorizin-perfused (filled pink square) hearts under the pre-ischemic baseline conditions and post-ischemic condition measured after 20-min reperfusion following 30-min global ischemia (baseline/post-ischemic condition, NFD: n = 4/n = 5, NFD with phlorizin-perfusion: n = 3/n = 5, HFD: n = 7/n = 7, and HFD with phlorizin-perfusion: n = 3/n = 7) *P < 0.05 and **P < 0.01 versus NFD hearts under post-ischemic conditions, †P < 0.05 versus HFD hearts under post-ischemic conditions, $$P < 0.01 versus corresponding controls at baseline

Full size image

Glucose utilization in the hearts during IRI

To test the functional significance of the contrasting changes in the plasma membrane expression of glucose transporters, we measured the myocardial glucose uptake (one of the major determinants of myocardial glucose utilization) before and after IRI [7]. At baseline, there were no significant between-group differences in the glucose uptake rate (Fig. 5d). In contrast, during ischemia–reperfusion, the cardiac glucose uptake was dramatically enhanced by the ischemic insult in NFD hearts, which was significantly attenuated in HFD hearts. This was thought to be mainly due to the blunted GLUT4 reaction to IRI. Of note, phlorizin considerably reduced the glucose uptake after IRI, particularly in HFD hearts compared to the other subjects (Fig. 5d). These data suggest that SGLT1 plays a critical role in myocardial glucose utilization during IRI, particularly under insulin-resistant conditions.

Discussion

In the present study using diet-induced obesity model, we showed that the inhibition of cardiac SGLT1 by phlorizin during the acute phase of IRI led to an impaired cardiac functional recovery and increased myocardial injury, which were associated with significant reductions in the myocardial glucose uptake enhanced by IRI. The novel findings of the present study are as follows: (i) the detrimental influence of phlorizin during IRI described above was more striking in subjects with diet-induced obesity than in normal subjects. (ii) This mechanistic connection was demonstrated by the blunted response of GLUT4 upregulation to IRI in contrast to the constant expression of SGLT1 in diet-induced obesity mouse hearts. (iii) In contrast to phlorizin, selective SGLT2-inhibitors did not significantly affect the cardiac functional recovery or myocardial injury after ischemia–reperfusion, even in diet-induced obesity mouse hearts, in which the SGLT2 expression was not detected. These data indicate the increasing reliance on SGLT1 for cardiac functional recovery and energy metabolism during IRI in insulin-resistant diabetic phenotypes, in which IRI-induced GLUT4 upregulation is compromised.

Various mechanisms underlying the detrimental influence of hyperglycemia under diabetic and/or insulin-resistant conditions on the myocardial function, structure, and energy metabolism have been intensively investigated [34,35,36,37]. One key point to note in the present isolated heart perfusion study is that the detrimental effects of HFD on these parameters became evident after ischemia–reperfusion, not being noted at baseline before ischemia. In this context, one possible mechanism is the compromised GLUT4 translocation. Previous studies showed that GLUT4 is an important mediator of enhanced glycolysis and maintaining ATP concentration under various pathological conditions, including IRI [2, 8, 9, 12]. However, significant decreases in the sarcolemmal GLUT4 expression were observed in insulin-resistant obese mouse hearts [13, 14], consistent with the present findings. Furthermore, we obtained the new finding that the GLUT4 upregulation in response to IRI insult was significantly attenuated in HFD mice, in association with the decreased myocardial glucose uptake after IRI. The impaired GLUT4 expression and translocation in diabetic subjects may involve not only disturbance of insulin signaling but also increased membrane cholesterol, reductions in membrane fluidity, and disruption of caveolae and caveolin-3 [34]. These findings may, at least in part, account for the impaired cardiac functional recovery and increased myocardial injury after ischemia–reperfusion in HFD hearts.

The same logic can be applied here: The present finding that an increased myocardial glucose uptake in response to IRI was blocked by phlorizin may be the main mechanism underlying the poor functional recovery and increased myocardial injury after ischemia–reperfusion. This aligns with our previous findings showing that cardiac SGLT1 is involved in an important protective mechanism against IRI by replenishing ATP stores in ischemic cardiac tissues via enhanced glucose utilization [7]. Consistent with a series of our studies, Connelly et al. showed that oral administration of a dual SGLT1/2-inhibitor led to an impaired cardiac function after myocardial infarction in a rat model with left anterior descending coronary artery ligation, while a selective SGLT2-inhibitor had no significant effect on this condition [38]. These data indicate that cardiac SGLT1 exerts protective effects against myocardial ischemia even in vivo, although they used a non-diabetic model rather than HFD-induced diabetic subjects. Furthermore, Kanwal et al. showed that SGLT1 inhibition by phlorizin abrogated the beneficial effect of ischemic preconditioning against IRI [39]. However, while cardiac SGLT1 does indeed exert favorable effects during the acute phase of IRI, its chronic excessive activation has been reported to have unfavorable effects [20,21,22,23, 25], thus suggesting that the time course of SGLT activation is critical for eliciting cardioprotective effects [7]. Indeed, Li et al. very recently reported that the RNAi-mediated knockdown of SGLT1 in cardiomyocytes is protective against IRI by reducing oxidative stress [24], although they found a similar exacerbation of IRI when using phlorizin. There may also be some compensatory mechanisms activated in those mouse hearts by the permanent knock-down of cardiac SGLT1 from birth. Considering that the SGLT1 expression is chronically increased under diabetic conditions [19, 21], resulting in detrimental effects [21, 25, 40], it is important to attain the effects of SGLT1 on the cardiac function as well as energy metabolism during acute phase of IRI, particularly in insulin-resistant diabetic models. We found in the present study that, under insulin-resistant conditions, SGLT1 isoform may play a compensatory protective role during the loss of GLUT4-mediated glucose uptake, rather than provides detrimental impacts on the diabetic myocardium [21, 25], at least during the acute phase of IRI.

Despite the absence of changes in the SGLT1 expression, even under insulin-resistant conditions, our results still indicate the possible role of SGLT1 activation in the cardiomyocytes (in addition to its translocation/internalization-mediated expression), considering that phlorizin exerted substantial effects on the cardiac functional recovery and injury as well as the myocardial glucose uptake after ischemia–reperfusion in the HFD-induced obese mice. However, the precise regulatory mechanisms by which SGLT1 develops tolerance to IRI under insulin-resistant conditions remain unclear. The cardiac SGLT1 is thought to be activated by various factors, such as insulin, AMP-activated protein kinase (AMPK), persistent hyperglycemia, as well as ischemia–reperfusion injury per se [18,19,20,21, 24, 40], all of which can also activate GLUT4. And thus, a pathway specific for cardiac SGLT1 activation has not yet been identified. Hypoxia-inducible factor 1α (HIF-1α), which is increased under diabetic as well as hypoxic conditions, is a major regulator of the GLUT1 expression (although the GLUT1 expression was not significantly affected in the present study; Additional file 1: Figs. S3 and S4). As such, it may play a potential role in regulating the SGLT1 activity in the heart, although it has recently been shown to diminish the SGLT1 and SGLT2 expression in kidneys [41], which is the opposite of what we might expect based on the findings of the present study. Future investigations should clarify the mechanisms underlying the regulation of the SGLT1 expression/activation in the cardiomyocytes in greater detail and identify the specific regulators and/or agents (namely, SGLT1-specific agonists) that transiently induce the expression/activation of cardiac SGLT1 during IRI, which may lead to potential therapeutic applications for the acute phase of IRI.

A recent series of large-scale clinical trials has shown that SGLT2-inhibitors have profound benefits on reducing the risk of cardiovascular events in patients with type 2 diabetes [31,32,33]. In this context, assessing the direct effects of SGLT2-inhibitors on the heart in the current experimental model has important clinical implications. We did not detect any SGLT2 expression, even in HFD mouse hearts, which explains that tofogliflozin, ipragliflozin, and canagliflozin, all of which are selective SGLT2-inhibitors, did not affect the cardiac functional recovery or myocardial injury after IRI. To confirm the safety and efficacy of these recently developed anti-diabetic agents, the dosage used in the current study was almost fivefold higher than the blood concentrations after a single oral dose of each SGLT2-inhibitor in clinical use. There is growing evidence showing the potential cardioprotective mechanisms of SGLT2-inhibitors, largely mediated through (as systemic effects) decreasing the insulin resistance by reducing the body fat mass, modulating natriuretic peptides, reducing arterial stiffness, modulating sympathetic tone, exerting renoprotective effects, and (as direct cardiac effects) reducing inflammation, oxidative stress, apoptosis, fibrosis, inhibiting sodium–hydrogen exchanger (NHE) [42,43,44]. The neutral effect of SGLT2-inhibitors in the present study can be partly explained by the fact that the current experimental model is an ex vivo isolated heart perfusion model, which eliminates the systemic effects of SGLT2-inhibitors. Meanwhile, a series of recent studies by Zuurbier et al. clearly showed that selective SGLT2-inhibitors directly inhibit cardiac NHE [45,46,47], although empagliflozin did not significantly affect the cardiac functional recovery or myocardial injury after ischemia–reperfusion, which is consistent with our findings; however, the authors did not examine any models of diet-induced obesity [45]. In addition, Lee et al. reported that dapagliflozin attenuated cardiac fibrosis by regulating macrophage polarization [48], although most macrophage and other blood cells were washed out in our present study model of Langendorff. Intriguingly, they indicated that dapagliflozin induced compensatory activation of SGLT1 as a cardio-protective mechanism, leading to a reduction in oxidative stress. Based on these previous findings, it is possible that, in our current study, selective SGLT2-inhibitors exerted direct cardioprotective effects, although further studies will be needed in order to investigate the effects of those pharmacological agents on cardiac NHE under diabetic insulin-resistant conditions as well as on cardiac fibrosis through histopathological analyses. Regardless, the present study investigated the transient local direct effects of SGLT2-inhibitors on the cardiac tissue during the acute phase of IRI; our findings therefore do not conflict with the consistent cardioprotective results from other in vivo experimental studies [44, 49,50,51,52,53,54,55,56] or clinical trials [31,32,33], all of which investigated the systemic effects of SGLT2-inhibitors over a longer period. Furthermore, the present findings suggest that potential mechanisms underlying the cardiovascular benefits of SGLT2-inhibitors may depend largely on the systemic inter-organ network, including cardiorenal syndrome [57,58,59].

GLUT1 is another major glucose transporter in the heart that is largely responsible for the basal cardiac glucose transport in an insulin-independent manner [6, 10]. Previous studies have shown that GLUT1 also exerts important cardioprotective actions, mainly in chronic pathological settings [15, 60]. Since GLUT1 is a facilitated energy-independent transporter that usually localizes to the plasma membrane, its expression at the plasma membrane is considered to directly reflect its activity. Given that we did not detect any significant change in the GLUT1 expression at the plasma membrane, regardless of the diet condition, GLUT1 may have a limited impact, at least in the present experimental model.

Some studies suggested that 2-DG might be a relatively poor substrate for SGLT1, although this glucose analog has been used for the glucose uptake assay of SGLTs in previous studies [7, 19, 61]. Thus, we cannot completely deny the possibility that impairment of cardiac glucose uptake by phlorizin may be due, at least in part, to the non-specific inhibition of other glucose transporters. However, a series of previous studies using phlorizin indicated that phlorizin does inhibit cardiac SGLT1 [25, 62,63,64]. Lambert et al. showed that 200 µM of phlorizin reduced the myocardial intracellular sodium concentration, which rules out any involvement in GLUTs (namely, sodium-independent glucose transporters) [21]. Furthermore, a relatively low dose of phlorizin was used in the present study compared to that used in the previous studies (200–10 mM) [21, 25, 39, 62, 63], thus minimizing the non-specific inhibitory effects of phlorizin on other glucose transporters. Finally, it is highly possible that phlorizin-perfusion specifically inhibits cardiac SGLT1 in the current ex vivo Langendorff model, since non-specific inhibitory effects on glucose transporters are observed only when phlorizin is broken down in the small intestine to its aglycone form, phloretin [65, 66]. In fact, the plasma membrane expression patterns of GLUT4 and GLUT1 were unchanged by phlorizin administration at all points of IRI under both diet conditions (Additional file 1: Fig. S4). Likewise, previous studies by other groups [22, 24] showed that there was no significant differences in the levels of membrane-associated GLUT1 or GLUT4 in mice with cardiomyocyte-specific knockdown of SGLT1, suggesting that the expression/activity of SGLT1 and GLUTs may be regulated independently, without any mutual interaction in the heart.

It is also important to assess the expression of those glucose transporters in isolated cardiomyocytes, considering that not only myocardial SGLT1 and other glucose transporters but also those residing in cardiac fibroblasts [40] and endothelial cells [67] may play a substantial role under diverse pathological conditions, such as ischemic heart diseases as well as diabetes (insulin resistant conditions), and the regulation of the expression of those glucose transporters might differ among cell types.

In this context, it would be interesting to clarify the effects of SGLT1 inhibition during IRI in vivo in order to examine its influence on the systemic inter-organ network as well as macrophages and other blood cells circulating coronary arteries. On the other hand, the Langendorff system is useful for evaluating the direct local effects of glucose transporters in the heart more clearly, as this system is not associated with changes in systemic substrate metabolism or neurohumoral factors activated under pathological conditions, such as diabetes.

Given these limitations associated with the present study, future investigations should conduct a series of experiments using a conditional (transient) cardiomyocyte-specific SGLT1 knockout model (rather than permanent knockdown from birth) in order to clarify the complete in vivo characterization of the relatively acute actions of SGLT1 in the cardiomyocytes.

Conclusions

We determined that the impairment of the cardiac functional recovery and increased myocardial injury associated with the reduction in the myocardial glucose uptake by phlorizin during IRI were more pronounced in diet-induced obese mice hearts than in the hearts of mice fed a normal diet, while no harmful effects induced by any SGLT2-inhibitors were observed in the same setting. Given that SGLT1 and GLUTs function independently without any mutual interaction, at least under the conditions in the present study, there is an increasing reliance on SGLT1 for cardiac functional recovery after ischemia–reperfusion via enhanced myocardial glucose utilization, particularly under insulin-resistant conditions, in which GLUT4 upregulation in response to IRI is compromised.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

2-DG:

2-deoxy-d-glucose

AAR:

area at risk

AMPK:

AMP-activated protein kinase

ATP:

adenosine triphosphate

AUC:

area under the curve

Cana:

canagliflozin

CPK:

creatine phosphokinase

DMSO:

dimethylsulfoxide

+dp/dtmax :

maximum rate of contraction

−dp/dtmin :

maximum rate of relaxation

GAPDH:

glyceraldehyde 3-phosphate dehydrogenase

GLUT:

facilitated glucose transporter

HFD:

high-fat diet

HIF-1α:

hypoxia-inducible factor 1α

HR:

heart rate

I:

ischemia

Ipra:

ipragliflozin

IRI:

ischemia–reperfusion injury

LVDP:

left ventricular developed pressure

LVEDP:

left ventricular end-diastolic pressure

LVSP:

left ventricular systolic pressure

min:

minutes

NFD:

normal-fat diet

QRT-PCR:

quantitative reverse transcription polymerase chain reaction

R:

reperfusion

RNA:

ribonucleic acid

RPP:

rate pressure product

SGLT:

sodium–glucose cotransporter

SGLT2i:

SGLT2-inhibitor

Tofo:

tofogliflozin

TTC:

triphenyltetrazolium chloride

References

  1. 1.

    Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99(4):578–88.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Tian R, Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation. 2001;103(24):2961–6.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–129.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Nagoshi T, Yoshimura M, Rosano GM, Lopaschuk GD, Mochizuki S. Optimization of cardiac metabolism in heart failure. Curr Pharm Des. 2011;17:3846–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Heywood SE, Richart AL, Henstridge DC, Alt K, Kiriazis H, Zammit C, Carey AL, Kammoun HL, Delbridge LM, Reddy M, et al. High-density lipoprotein delivered after myocardial infarction increases cardiac glucose uptake and function in mice. Sci Transl Med. 2017;9(411):e6084.

    Article  CAS  Google Scholar 

  6. 6.

    Szablewski L. Glucose transporters in healthy heart and in cardiac disease. Int J Cardiol. 2017;230:70–5.

    PubMed  Article  Google Scholar 

  7. 7.

    Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka TD, Ito K, Harada T, Takahashi H, Ikegami M, Anzawa R, Yoshimura M. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia–reperfusion injury in mice. PLoS ONE. 2015;10(6):e0130605.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  8. 8.

    Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104(3):330–5.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Matsui T, Nagoshi T, Hong EG, Luptak I, Hartil K, Li L, Gorovits N, Charron MJ, Kim JK, Tian R, et al. Effects of chronic Akt activation on glucose uptake in the heart. Am J Physiol Endocrinol Metab. 2006;290(5):E789–97.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Shao D, Tian R. Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol. 2015;6(1):331–51.

    PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, Del Monte F, Gwathmey JK, Grazette L, et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Investig. 2005;115(8):2128–38.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Wende AR, Kim J, Holland WL, Wayment BE, O’Neill BT, Tuinei J, Brahma MK, Pepin ME, McCrory MA, Luptak I, et al. Glucose transporter 4-deficient hearts develop maladaptive hypertrophy in response to physiological or pathological stresses. Am J Physiol Heart Circ Physiol. 2017;313(6):H1098–108.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  13. 13.

    Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, Theobald HA, Cooksey RC, Kandror KV, et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res. 2009;82(2):351–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Cook SA, Varela-Carver A, Mongillo M, Kleinert C, Khan MT, Leccisotti L, Strickland N, Matsui T, Das S, Rosenzweig A, et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J. 2010;31(1):100–11.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Liao R, Jain M, Cui L, D’Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106(16):2125–31.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Zhou L, Cryan EV, D’Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90(2):339–46.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–94.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M, Mannucci E. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol. 2017;243:86–90.

    PubMed  Article  Google Scholar 

  19. 19.

    Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84(1):111–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Banerjee SK, Wang DW, Alzamora R, Huang XN, Pastor-Soler NM, Hallows KR, McGaffin KR, Ahmad F. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J Mol Cell Cardiol. 2010;49(4):683–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport. J Am Heart Assoc. 2015;4(9):e002183.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  22. 22.

    Ramratnam M, Sharma RK, D’Auria S, Lee SJ, Wang D, Huang XY, Ahmad F. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc. 2014;3(4):e000899.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  23. 23.

    Matsushita N, Ishida N, Ibi M, Saito M, Sanbe A, Shimojo H, Suzuki S, Koepsell H, Takeishi Y, Morino Y, et al. Chronic pressure overload induces cardiac hypertrophy and fibrosis via increases in SGLT1 and IL-18 gene expression in mice. Int Heart J. 2018;59:1123–33.

    PubMed  CAS  Article  Google Scholar 

  24. 24.

    Li Z, Agrawal V, Ramratnam M, Sharma RK, D’Auria S, Sincoular A, Jakubiak M, Music ML, Kutschke WJ, Huang XN, et al. Cardiac sodium–glucose co-transporter 1 (SGLT1) is a novel mediator of ischemia/reperfusion injury. Cardiovasc Res. 2019;56:56. https://doi.org/10.1093/cvr/cvz037 (in Press).

    Article  Google Scholar 

  25. 25.

    Balteau M, Tajeddine N, de Meester C, Ginion A, Des Rosiers C, Brady NR, Sommereyns C, Horman S, Vanoverschelde JL, Gailly P, et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res. 2011;92(2):237–46.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Yoshino T, Nagoshi T, Anzawa R, Kashiwagi Y, Ito K, Katoh D, Fujisaki M, Kayama Y, Date T, Hongo K, et al. Preconditioning actions of aldosterone through p38 signaling modulation in isolated rat hearts. J Endocrinol. 2014;222(2):289–99.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Nagoshi T, Date T, Fujisaki M, Yoshino T, Sekiyama H, Ogawa K, Kayama Y, Minai K, Komukai K, Ogawa T, et al. Biphasic action of aldosterone on Akt signaling in cardiomyocytes. Horm Metab Res. 2012;44:931–7.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Kimura H, Nagoshi T, Yoshii A, Kashiwagi Y, Tanaka Y, Ito K, Yoshino T, Tanaka TD, Yoshimura M. The thermogenic actions of natriuretic peptide in brown adipocytes: the direct measurement of the intracellular temperature using a fluorescent thermoprobe. Sci Rep. 2017;7(1):12978.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  29. 29.

    Thakker GD, Frangogiannis NG, Bujak M, Zymek P, Gaubatz JW, Reddy AK, Taffet G, Michael LH, Entman ML, Ballantyne CM. Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291(5):H2504–14.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Aoyagi T, Higa JK, Aoyagi H, Yorichika N, Shimada BK, Matsui T. Cardiac mTOR rescues the detrimental effects of diet-induced obesity in the heart after ischemia–reperfusion. Am J Physiol Heart Circ Physiol. 2015;308(12):H1530–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Russell J, Du Toit EF, Peart JN, Patel HH, Headrick JP. Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection. Cardiovasc Diabetol. 2017;16(1):155.

    PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy. Circ Res. 2018;122(4):624–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Chong CR, Clarke K, Levelt E. Metabolic remodeling in diabetic cardiomyopathy. Cardiovasc Res. 2017;113(4):422–30.

    CAS  PubMed Central  Article  Google Scholar 

  37. 37.

    Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech. 2009;2(9–10):454–66.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Connelly KA, Zhang Y, Desjardins J-F, Thai K, Gilbert RE. Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc Diabetol. 2018;17(1):99.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Kanwal A, Nizami HL, Mallapudi S, Putcha UK, Mohan GK, Banerjee SK. Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia–reperfusion injury. Biochem Biophys Res Commun. 2016;472(2):392–8.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Meng L, Uzui H, Guo H, Tada H. Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. Mol Med Rep. 2018;17(5):6887–92.

    CAS  PubMed  Google Scholar 

  41. 41.

    Zapata-Morales JR, Galicia-Cruz OG, Franco M, Martinez YMF. Hypoxia-inducible factor-1alpha (HIF-1alpha) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia. J Biol Chem. 2014;289(1):346–57.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation. 2016;134(10):752–72.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Lahnwong S, Chattipakorn SC, Chattipakorn N. Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors. Cardiovasc Diabetol. 2018;17(1):101.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, Wang BH, Liew D. Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc Res. 2019;115(2):266–76.

    PubMed  Article  Google Scholar 

  45. 45.

    Uthman L, Nederlof R, Eerbeek O, Baartscheer A, Schumacher C, Buchholtz N, Hollmann MW, Coronel R, Weber NC, Zuurbier CJ. Delayed ischemic contracture onset by empagliflozin associates with NHE-1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc Res. 2019. https://doi.org/10.1093/cvr/cvz004 (in Press).

    PubMed  Article  Google Scholar 

  46. 46.

    Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722–6.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2016;60(3):568–73.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  48. 48.

    Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13(1):148.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  50. 50.

    Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  51. 51.

    Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, Dollet L, Le May C, Toumaniantz G, Manrique A, et al. The sodium–glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66(4):1030–40.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  53. 53.

    Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, et al. Empagliflozin increases cardiac energy production in diabetes. JACC Basic Transl Sci. 2018;3(5):575–87.

    PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia–reperfusion injury. J Endocrinol. 2018;236(2):69–84.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Adingupu DD, Gopel SO, Gronros J, Behrendt M, Sotak M, Miliotis T, Dahlqvist U, Gan LM, Jonsson-Rylander AC. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(−/−) mice. Cardiovasc Diabetol. 2019;18(1):16.

    PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.

    PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985–7.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Yan J, Young ME, Cui L, Lopaschuk GD, Liao R, Tian R. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation. 2009;119(21):2818–28.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Kanwal A, Singh SP, Grover P, Banerjee SK. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2. Anal Biochem. 2012;429(1):70–5.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    von Lewinski D, Gasser R, Rainer PP, Huber MS, Wilhelm B, Roessl U, Haas T, Wasler A, Grimm M, Bisping E, et al. Functional effects of glucose transporters in human ventricular myocardium. Eur J Heart Fail. 2010;12(2):106–13.

    Article  CAS  Google Scholar 

  63. 63.

    von Lewinski D, Rainer PP, Gasser R, Huber MS, Khafaga M, Wilhelm B, Haas T, Machler H, Rossl U, Pieske B. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism. 2010;59(7):1020–8.

    Article  CAS  Google Scholar 

  64. 64.

    Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y. Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther. 2016;358(1):94–102.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723–9.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, Day EA, Salt IP, Steinberg GR, Hardie DG. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–94.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    Elfeber K, Stumpel F, Gorboulev V, Mattig S, Deussen A, Kaissling B, Koepsell H. Na(+)-d-glucose cotransporter in muscle capillaries increases glucose permeability. Biochem Biophys Res Commun. 2004;314(2):301–5.

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Sanofi K.K. (Tokyo), Astellas Pharma Inc. (Ibaraki), and Mitsubishi Tanabe Pharma Co. (Osaka) for supplying tofogliflozin, ipragliflozin, and canagliflozin, respectively.

Funding

This study was supported in part by grants-in-aid for the Ministry of Education, Culture, Sports, Science and Technology [JP17K09531] (to T. Nagoshi).

Author information

Affiliations

  1. Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan

    Akira Yoshii, Tomohisa Nagoshi, Yusuke Kashiwagi, Haruka Kimura, Yoshiro Tanaka, Yuhei Oi, Keiichi Ito, Takuya Yoshino, Toshikazu D. Tanaka & Michihiro Yoshimura

Authors
  1. Akira Yoshii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomohisa Nagoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuke Kashiwagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haruka Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiro Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuhei Oi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keiichi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takuya Yoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshikazu D. Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michihiro Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AY, TN, and MY conceived and designed the study, contributed to the writing of the manuscript. AY, TN, YK, HK, YT, and YO conducted experiments, contributed to the acquisition and interpretation of data. KI, TY, and TDT analysed and interpreted the data, and critically revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Tomohisa Nagoshi.

Ethics declarations

Ethics approval and consent to participate

All animal procedures conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Research Committee at the Jikei University School of Medicine (2016-038C4).

Consent for publication

Not applicable.

Competing interests

Michihiro Yoshimura reports that there are any relevant conflicts of interest. Outside the submitted work, there are personal fees from Mochida Pharmaceutical Co., Ltd, personal fees from MSD K.K., grants and personal fees from Kyowa Hakko Kirin Co., Ltd., grants and personal fees from Pfizer Japan Inc., grants and personal fees from Daiichi Sankyo Healthcare Co., Ltd., grants and personal fees from Sumitomo Dainippon Pharma Co., Ltd., grants from Nippon Boehringer Ingelheim Co., Ltd., grants from Otsuka Pharmaceutical Co., Ltd., grants from Teijin Pharma Limited, personal fees from Fujiyakuhin Co., Ltd., grants and personal fees from AstraZeneca K.K., personal fees from Taisho Toyama Pharmaceutical Co., Ltd., grants from Astellas Pharma Inc., personal fees from Mitsubishi Tanabe Pharma Corporation, grants from Shionogi & Co., Ltd., grants from Ono Pharmaceutical Co., Ltd. Tomohisa Nagoshi also reports that there are any relevant conflicts of interest. Outside the submitted work, there are grants from Daiichi Sankyo Healthcare Co., Ltd., from Nippon Boehringer Ingelheim Co., Ltd., and from Mitsubishi Tanabe Pharma Corporation.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1: Table S1.

Baseline cardiac function of perfused hearts with or without SGLT2-inhibitors perfusion in HFD-fed mice. Table S2. Baseline cardiac function of perfused hearts with or without tofogliflozin perfusion in normal chow-fed mice. Fig. S1. The profiles of other hemodynamic parameters. The profiles of RPP (A), LVEDP (B), and positive and negative dp/dt (C) measured at the indicated time points during ischemia–reperfusion in NFD (open black square; n = 6), NFD phlorizin-perfused (filled black square; n = 6), HFD (open pink square; n = 8), and HFD phlorizin-perfused (filled pink square; n = 8) hearts are shown. *P < 0.05 and **P < 0.01 versus NFD group at each time point; †P < 0.05 and ‡P < 0.01 versus HFD group at each time point. min, minutes; RPP, rate pressure product; LVEDP, left ventricular end-diastolic pressure. Fig. S2. SGLT2 mRNA was not detected in the heart from both NFD and HFD mice. The quantitative reverse transcription polymerase chain reaction (QRT-PCR) data indicating the SGLT2 gene expression levels in the hearts from either NFD (A) or HFD (B), or in the mouse intestine as the negative control and in the kidney as the positive control (C) (n = 3 each). (D) The QRT-PCR data were normalized to GAPDH. The data are shown as the fold change normalized to the levels found in the kidney (C). Fig. S3. Expression of GLUT1 in the murine hearts during ischemia–reperfusion. Representative immunoblots of GLUT1 in the plasma membrane fraction from the murine perfused hearts at baseline period measured at the end of the 10-minute pre-ischemia perfusion (A), and before and after IRI (B) are shown. (C) Densitometric quantitation normalized to the level of GLUT1 expression in NFD hearts before IRI is shown (NFD or HFD without IRI; n = 5 each, with IRI; n = 3 each). In both (A) and (B), immunoblots of Na+/K+ ATPase from the same membrane are shown as a loading control for the membrane fraction. Fig. S4. Expression of GLUT4, SGLT1 and GLUT1 in murine hearts during ischemia–reperfusion with or without phlorizin-perfusion. Representative immunoblots of GLUT4, SGLT1 and GLUT1 in the plasma membrane fraction from the murine perfused hearts before and after IRI with or without phlorizin-perfuion (A) are shown. The immunoblot of Na+/K+ ATPase from the same membrane are shown as a loading control for the membrane fraction. (B) Densitometric quantitation normalized to the level of either GLUT4, SGLT1 or GLUT1 expression in NFD hearts before IRI are shown (n = 3 each). *P < 0.05, **P < 0.01 versus NFD hearts without phlorizin perfusion before IRI; #P < 0.05 versus NFD hearts with phlorizin perfusion before IRI; ‡P < 0.01 versus NFD hearts without phlorizin perfusion after IRI; §P < 0.05 versus NFD hearts with phlorizin perfusion after IRI.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yoshii, A., Nagoshi, T., Kashiwagi, Y. et al. Cardiac ischemia–reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Cardiovasc Diabetol 18, 85 (2019). https://doi.org/10.1186/s12933-019-0889-y

Download citation

Keywords

  • SGLT1
  • Phlorizin
  • SGLT2-inhibitor
  • GLUT4
  • Insulin resistance
  • Ischemia–reperfusion injury
  • Glucose uptake

Cardiovascular Diabetology

ISSN: 1475-2840